From Molecule to Market Treehill CEO Highlights Full Spectrum Diligence as Key to Biotech Funding
June 20, 2025 | Friday | Opinion | By Manasee Kurlekar
At BIO 2025 Dr Ali Pashazadeh underscores the rising investor focus on operational execution and transaction readiness where scientific promise alone no longer secures capital
Dr Ali Pashazadeh, CEO, Treehill
As capital markets tighten across biotech, investors are increasingly selective not only about scientific potential but also about operational execution. At US BIO 2025, BioSpectrum spoke with Dr Ali Pashazadeh, CEO, Treehill about their approach to helping biotechs bridge this crucial gap.
With experience from 135 completed transactions, Dr Pashazadeh reiterated the need for operating at the intersection of scientific assessment, operational strategy, and capital formation. This model reflects the reality: investors demand confidence across the entire value chain — from molecule to market.
"The science may spark initial interest," Dr Ali Pashazadeh tells BioSpectrum. "But funding decisions are made after evaluating the CRO network, manufacturing readiness, clinical protocol viability, target product profile, and the management team's capacity to deliver."
At BIO 2025, Treehill spoke with Biospectrum regarding the path that biopharma innovators need to follow for achieving investment readiness. Young bio-busineses increasingly understand that transaction readiness now requires full-spectrum diligence. This model is becoming even more relevant as late-stage capital concentrates on fewer, better-de-risked assets.
Preparation for fundraising increasingly means preparing it for operational credibility, not simply presenting the scientific promise. In today's environment, the ability to move seamlessly from compelling science to a fully investable business proposition is a critical competitive advantage.
